Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

NCT02498652 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout

Interventions

DRUG: RDEA3170 2.5 mg
DRUG: allopurinol 300 mg

Sponsor

Ardea Biosciences, Inc.